Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.
Three small-cap biotechs with attractive risk/reward profiles.
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.